[go: up one dir, main page]

MY187735A - Compositions and methods for treating hepatitis c virus - Google Patents

Compositions and methods for treating hepatitis c virus

Info

Publication number
MY187735A
MY187735A MYPI2014001520A MYPI2014001520A MY187735A MY 187735 A MY187735 A MY 187735A MY PI2014001520 A MYPI2014001520 A MY PI2014001520A MY PI2014001520 A MYPI2014001520 A MY PI2014001520A MY 187735 A MY187735 A MY 187735A
Authority
MY
Malaysia
Prior art keywords
virus
subject
effective amount
methods
hepatitis
Prior art date
Application number
MYPI2014001520A
Inventor
Darryl G Cleary
Charles J Reynolds
Miriam Michelle Berrey
Robert G Hindes
William T Symonds
Adrian S Ray
Hongmei Mo
Christy M Hebner
Reza Oliyai
Vahid Zia
Dimitrios Stefanidis
Rowchanak Pakdaman
Melissa Jean Casteel
Original Assignee
Gilead Pharmasset Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2012/055621 external-priority patent/WO2013040492A2/en
Application filed by Gilead Pharmasset Llc filed Critical Gilead Pharmasset Llc
Publication of MY187735A publication Critical patent/MY187735A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Disclosed herein are a composition and unit dosage form for the treatment of hepatitis C virus (HCV) infection comprising GS-7977 and at least one pharmaceutically acceptable excipient, as well as methods for making said composition and unit dosage form. Also disclosed herein is a method for treating a subject, preferably a human, infected with hepatitis C virus, said method comprising administering to the subject for a time period an effective amount of GS-7977 and an effective amount of ribavirin. In one aspect, the method comprises administering to the subject an interferon-free treatment regimen comprising an effective amount of GS-7977 and an effective amount of ribavirin. In a particular aspect, the method is sufficient to produce an undetectable amount of HCV RNA in the subject for at least 12 weeks after the end of the time pe1iod.
MYPI2014001520A 2011-11-29 2012-11-27 Compositions and methods for treating hepatitis c virus MY187735A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161564500P 2011-11-29 2011-11-29
PCT/US2012/055621 WO2013040492A2 (en) 2011-09-16 2012-09-14 Methods for treating hcv
US201261707459P 2012-09-28 2012-09-28

Publications (1)

Publication Number Publication Date
MY187735A true MY187735A (en) 2021-10-15

Family

ID=48803225

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2014001520A MY187735A (en) 2011-11-29 2012-11-27 Compositions and methods for treating hepatitis c virus

Country Status (4)

Country Link
AP (1) AP2014007699A0 (en)
EC (1) ECSP21087299A (en)
IL (1) IL232889A (en)
MY (1) MY187735A (en)

Also Published As

Publication number Publication date
IL232889A (en) 2016-07-31
IL232889A0 (en) 2014-07-31
ECSP21087299A (en) 2022-02-25
AP2014007699A0 (en) 2014-06-30

Similar Documents

Publication Publication Date Title
PH12014501133A1 (en) Compositions and methods for treating hepatitis c virus
PH12019500289A1 (en) Vaccines directed against a human enteroviruses
MY160130A (en) Hepatitis c virus inhibitors
TN2013000421A1 (en) 2'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
MX2012004032A (en) Compounds for the treatment of hepatitis c.
TN2012000358A1 (en) Hepatitis c virus inhibitors
MX2013001579A (en) Hepatitis c virus inhibitors
TN2012000264A1 (en) Hepatitis c virus inhibitors
TN2012000214A1 (en) Hepatitis c virus inhibitors
MX2011008045A (en) Hepatitis c virus inhibitors.
MY152971A (en) Hepatitis c virus inhibitors
EP2555622A4 (en) Hepatitis c virus inhibitors
MX2012003171A (en) Novel macrocyclic inhibitors of hepatitis c virus replication.
MY202109A (en) Viral replication inhibitors
MX337936B (en) Hepatitis c virus inhibitors.
MX2012008652A (en) Therapies for treating hepatitis c virus infection.
IN2012MN02896A (en)
AR088580A1 (en) METHODS AND COMPOSITIONS TO TREAT HEPATITIS C VIRUS
PH12013502177A1 (en) Hepatitis c virus inhibitors
NZ630831A (en) Compositions and methods for administration of vaccines against dengue virus
RU2013120345A (en) NEW METHODS FOR TREATING INFECTIONS CAUSED BY HEPATITIS C VIRUS
MY187735A (en) Compositions and methods for treating hepatitis c virus
UA114097C2 (en) COMPOSITION (OPTIONS) AND METHOD (OPTIONS) OF TREATMENT OF VIRAL HEPATITIS C
MA20150030A1 (en) Compositions and methods for treating hepatitis c virus
UA47947U (en) Method for treating chronic viral hepatitis b and c in children